Anti-CTLA-1 and anti-PD-1 therapies have been the most extensively researched due to documented benefits for melanoma treatment as evidenced by higher rates of tumor clearance and, crucially, long term disease eradication in some patients compared with traditional treatments (129). Here, PDCD1 is linked to melanoma.